Re: Amy Lockefeer, Arianne Schild, Swapneel Anaokar, et al. Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2026.01.010
European Urology Focus · 2026-06 · 12 (3) · 620-621
DOI: 10.1016/j.euf.2026.03.010 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Urology Focus, 2026-06. Verfasst von Neeraj Singh und 1 weiteren Autor:innen. Beteiligte Einrichtung: Dr. D. Y. Patil Medical College Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed-to-be-University), Pimpri, Pune, Maharashtra, India.…. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Dr. D. Y. Patil Medical College Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed-to-be-University), Pimpri, Pune, Maharashtra, India. Electronic address: neeraj.singh.work@proton.me.
- Dr. D. Y. Patil Dental College and Hospital, Dr. D. Y. Patil Vidyapeeth (Deemed-to-be-University), Pimpri, Pune, Maharashtra, India.
Zitieren
APA
Singh, N., & Srivastav, M. (2026). Re: Amy Lockefeer, Arianne Schild, Swapneel Anaokar, et al. Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2026.01.010. European Urology Focus, 12(3), 620-621. https://doi.org/10.1016/j.euf.2026.03.010
Vancouver
Singh N, Srivastav M. Re: Amy Lockefeer, Arianne Schild, Swapneel Anaokar, et al. Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2026.01.010. European Urology Focus. 2026;12(3):620-621. doi:10.1016/j.euf.2026.03.010
BibTeX
@article{Singh2026,
author = {Singh, Neeraj and Srivastav, Monika},
title = {Re: Amy Lockefeer, Arianne Schild, Swapneel Anaokar, et al. Efficacy and Safety of Mirabegron in Patients with Overactive Bladder and Cardiovascular Comorbidities: A Post Hoc Analysis of Randomised Trials. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2026.01.010},
journal = {European Urology Focus},
year = {2026},
volume = {12},
number = {3},
pages = {620--621},
doi = {10.1016/j.euf.2026.03.010}
}
EUVIMED